ArticleGland surgery2021
Prediction of treatment responses to neoadjuvant chemotherapy in breast cancer using contrast-enhanced ultrasound.
Article in Gland surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Ultrasound for predicting pathological response to neoadjuvant chemotherapy in patients with breast cancer: a systematic review and meta-analysis.BMC cancer · 2026Pooled it
- Feasibility of deep learning-based cancer detection in ultrasound microvascular images.Ultrasonics · 2026Article
- Advances in ultrasound for preoperative molecular subtyping of malignant breast tumors.Frontiers in oncology · 2026Review
- Diagnostic performance of shear wave elastography and contrast-enhanced ultrasound in evaluating the pathological response of breast cancer patients to neoadjuvant chemotherapy: a meta-analysis.Quantitative imaging in medicine and surgery · 2025Article
- An ultrasound-based model for predicting the response to neoadjuvant chemotherapy in early stage triple negative breast cancer patients.BMC medical imaging · 2025Article
- Prediction models of breast cancer molecular subtypes based on multimodal ultrasound and clinical features.BMC cancer · 2025Article
- Prediction of neoadjuvant chemotherapy efficacy in breast cancer: integrating multimodal imaging and clinical features.BMC medical imaging · 2025Article
- Current status and future perspectives of contrast-enhanced ultrasound diagnosis of breast lesions.Journal of medical ultrasonics (2001) · 2024Review
- Association and predictive value of contrast‑enhanced ultrasound features with axillary lymph node metastasis in primary breast cancer.Oncology letters · 2024Article
- Deep Learning of Multimodal Ultrasound: Stratifying the Response to Neoadjuvant Chemotherapy in Breast Cancer Before Treatment.The oncologist · 2024Article
- Advantages of contrast-enhanced ultrasound in the localization and diagnostics of sentinel lymph nodes in breast cancer.Journal of Zhejiang University. Science. B · 2023Article
- The Role of Ultrasound Features in Predicting the Breast Cancer Response to Neoadjuvant Chemotherapy.Cureus · 2023Article
- Correlation between Baseline Conventional Ultrasounds, Shear-Wave Elastography Indicators, and Neoadjuvant Therapy Efficacy in Triple-Negative Breast Cancer.Diagnostics (Basel, Switzerland) · 2023Article
- Multiparametric Contrast-Enhanced Ultrasound in Early Prediction of Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival in Breast Cancer.Diagnostics (Basel, Switzerland) · 2023Article
- Article
- Advances in Imaging in Evaluating the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundElucidation the efficacy of neoadjuvant chemotherapy (NAC) in breast cancer is important for informing therapeutic decisions. This study aimed at evaluating the potential value of contrast-enhanced ultrasound (CEUS) parameters in predicting breast cancer responses to NAC.
methodsWe performed CEUS examinations before and after two cycles of NAC. Quantitative CEUS parameters [maximum intensity (IMAX), rise time (RT), time to peak (TTP), and mean transit time (mTT)], tumor diameter, and their changes were measured and compared to histopathological responses, according to the Miller-Payne Grading (MPG) system (score 1, 2, or 3: minor response; score 4 or 5: good response). Prediction models for good response were developed by multiple logistic regression analysis and internally validated through bootstrap analysis. The receiver operating characteristic (ROC) curve was used to evaluate the performance of prediction models.
resultsA total of 143 patients were enrolled in this study among whom 98 (68.5%) achieved a good response and while 45 (31.5%) exhibited a minor response. Several imaging variables including diameter, IMAX, changes in diameter (Δdiameter), IMAX (ΔIMAX) and TTP (ΔTTP) were found to be significantly associated with good therapeutic responses (P<0.05). The areas under the curve (AUC) increased from 0.748 to 0.841 in the multivariate model that combined CEUS parameters and molecular subtypes with a sensitivity and specificity of 0.786, 0.745, respectively. Tumor molecular subtype was the primary predictor of primary endpoint.
conclusionsCEUS is a potential tool for predicting responses to NAC in locally advanced breast cancer patients. Compared to the other molecular subtypes, triple negative and HER2+/ER- subtypes are more likely to exhibit a good response to NAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.